Details

Autor(en) / Beteiligte

• Smith, B Douglas
• Beach, Charles L
• Mahmoud, Dalia
• Weber, Laura
• Henk, Henry J

Titel

Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis

Ist Teil von

• Experimental hematology & oncology, 2014-03, Vol.3 (1), p.10-10, Article 10

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2014

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment. A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or azacitidine between January 2006 and June 2012. Treatment with azacitidine was associated with a longer median overall survival (10.1 versus 6.9 mos., p = 0.007) and a lower risk of hospitalization (HR 0.787, p = 0.02) compared to treatment with decitabine. This analysis of the outcomes of real-world treatment of AML patients with demethylating agents suggests that azacitidine may result in clinically superior outcomes than decitabine.